What’s new in lipid management for people with LDL cholesterol levels ≥2.6 mmol/L or heterozygous familial hypercholesterolemia (FH)?

Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine.

This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with high LDL cholesterol (≥2.6 mmol/L) or heterozygous FH. Our experts also take a closer look at why this patient subgroup is at particularly high cardiovascular risk and the importance identifying patients with family history or genetic causes of dyslipidemia. They also discuss how this patient subgroup may benefit from early intensive treatment approaches, such as ezetimibe and PCSK9 inhibitors, to reduce their risk for further cardiovascular complications.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr.  Thanassoulis:

• Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence.

Dr. Manjoo:

• Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.